Until very few years ago, the oncology community dogmatically excluded any clinical
potential for immunotherapy in controlling brain metastases. Therefore, despite the …

Abstract Programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) are target molecules
for immunotherapy in non-small cell lung cancer. PD-L1 is expressed not only in cancer …

Introduction Immune therapy has shown good results in small-cell lung cancer (SCLC), but
the impact of immune microenvironment of the disease is unclear. In this work, we detected …

The latest literature demonstrates the predominant role of the programmed cell death axis
(PD-1/PD-L1/PD-L2) in ovarian cancer (OC) pathogenesis. However, data concerning this …

Introduction The programmed death-ligand 1 (PD-L1) immune checkpoint inhibitors,
atezolizumab and durvalumab, have received regulatory approval for the first-line treatment …

New therapeutics targeting immune checkpoint proteins have significantly advanced
treatment of non-small cell lung cancer (NSCLC), but protein level quantitation of drug …

Abstract Background Small Cell Lung Cancer (SCLC) is one of the most aggressive thoracic
malignancies and has been very challenging in developing personalized medicine. While …

Background Despite recent progresses in immune checkpoint blockade (ICB) in small-cell
lung cancer (SCLC), a lack of understanding regarding the systemic tumor immune …

Introduction: the objective was to evaluate the impact of IDH1 R132H mutation, MGMT
methylation and PD-L1 expression in high grade glioma that received standard therapy …

Objectives Prevalence of tumor PD-L1 expression in extensive-stage small-cell lung cancer
(ES-SCLC) is variable, and data on PD-L2 expression are limited. The prognostic values of …